Keros Therapeutics Target of Unusually Large Options Trading (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of unusually large options trading on Thursday. Investors acquired 2,688 call options on the stock. This is an increase of 3,532% compared to the typical volume of 74 call options.

Analysts Set New Price Targets

Several brokerages have weighed in on KROS. Guggenheim reissued a “buy” rating and set a $102.00 price objective (up from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, Wells Fargo & Company boosted their target price on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $85.67.

Hedge Funds Weigh In On Keros Therapeutics

Large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Keros Therapeutics during the 2nd quarter worth approximately $1,118,000. Intech Investment Management LLC bought a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $603,000. Bank of New York Mellon Corp raised its stake in shares of Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after purchasing an additional 18,755 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Shares of KROS opened at $18.83 on Friday. The stock has a 50 day simple moving average of $59.11 and a 200 day simple moving average of $52.63. Keros Therapeutics has a 52-week low of $15.67 and a 52-week high of $73.00. The firm has a market capitalization of $762.75 million, a PE ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same period in the prior year, the business posted ($1.33) earnings per share. The firm’s revenue was up 4750.0% on a year-over-year basis. Equities research analysts predict that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.